CLINICAL TRIALS PROFILE FOR SEEBRI
✉ Email this page to a colleague
All Clinical Trials for SEEBRI
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT02512302 ↗ | Study to Determine the Amount of Glycopyrrolate Absorbed in the Lungs After Taking the Medicine With a eFlow Nebulizer and Seebri® Breezhaler® With and Without Activated Charcoal in Subjects With Moderate to Severe Chronic Obstructive Pulmonary Di | Completed | Sunovion Respiratory Development Inc. | Phase 1 | 2015-10-01 | The purpose of this research study is to determine the amount of medicine absorbed in the lungs following dosing via eFlow nebulizer and Seebri® Breezhaler® with and without activated charcoal in subjects with moderate to severe chronic obstructive pulmonary disease (COPD). |
| NCT02622243 ↗ | Duration of Long Acting Muscarinic Antagonist (LAMA) Bronchoprotection Against Methacholine Challenge | Completed | University of Saskatchewan | Phase 4 | 2015-11-01 | The study will assess the duration of protection of single doses of 2 different long acting muscarinic antagonists against methacholine induced bronchoconstriction. |
| NCT02953041 ↗ | Effect of a LAMA and a uLABA on the Methacholine Dose-response Curve | Completed | University of Saskatchewan | Phase 4 | 2016-10-01 | The study will assess the effects of two drugs, glycopyrronium and indacaterol, taken either as monotherapy or in combination, on the methacholine dose-response curve. This will allow for further elucidation of the mechanisms of each drug in human participants. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for SEEBRI
Condition Name
Clinical Trial Locations for SEEBRI
Clinical Trial Progress for SEEBRI
Clinical Trial Phase
Clinical Trial Sponsors for SEEBRI
Sponsor Name
